Proposal for Guidelines for the Treatment of Vitiligo in Croatia
DOI:
https://doi.org/10.12970/2310-998X.2014.02.01.4Keywords:
Depigmentation, melanocytes, vitiligo, guidelines, Croatia.Abstract
Vitiligo, an acquired depigmentation disorder, because of its impressive clinical presentation has a large impact on psychosocial life of patients. Although the exact etiopathogenesis still remains uncertain, several therapeutic options are available for treatment of this condition. Unfortunately, patients are often confronted with difficulties regarding to receiving suitable therapy. Because of the fact that vitiligo is not contagious and not life-threatening disease, physicians usually do not recognize patients’ problems and consider vitiligo as only a cosmetic problem, which should be treated only by camouflage and sun protection products. On the other hand, because of the lack of the accurate information for patients, a widely open market for different kind of alternative questionable therapies occurs so patients are often experimenting with different types of unproven medications. The need for widely accepted consensus concerning vitiligo treatment and establishment of the therapeutic guidelines exists worldwide. Our aim was to introduce for the first time vitiligo therapy guidelines in Republic of Croatia, based on the evidence-based accepted vitiligo therapy world recommendations and our experience. We present a review of therapy for vitiligo regarding to various vitiligo types and severity of lesions as well adequate therapeutic options. Also, our intention is to improve social component of patient’s life through rising awareness of this condition which affects over 35 million people worldwide.
References
Ortonne JP, Passeron T. Vitiligo and Other Disorders of Hypopigmentation. In: Bolognia JL, Jorizzo JL, Schaffer JV, ed. Dermatology 3rd ed. Edinburgh: Mosby 2012; 1023-1048.
Stanimirović A, Kovačević M. Vitiligo. In: Šitum M, edt. Smjernice u dijagnostici I liječenju najčešćih dermatoza I tumora kože. Zagreb: Naklada Slap 2012; 155-69.
Taieb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009; 360: 160-9. http://dx.doi.org/10.1056/NEJMcp0804388
Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview. J Am Acad Dermatol 2011; 65: 473-91. http://dx.doi.org/10.1016/j.jaad.2010.11.061
Schallreuter KU, Kruger C, Wurfel BA, Panske A, Wood JM. From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol 2008; 47: 743-53. http://dx.doi.org/10.1111/j.1365-4632.2008.03660.x
Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet 1994; 55: 981-90.
Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16: 208-14. http://dx.doi.org/10.1034/j.1600-0749.2003.00032.x
Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 11: 661-7.
Gregersen PK. Modern genetics, ancient defenses, and potential therapies. N Engl J Med 2007; 356: 1263-6. http://dx.doi.org/10.1056/NEJMe078017
Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010; 362: 1686-97. http://dx.doi.org/10.1056/NEJMoa0908547
Abdou AG, Maraee AH, Reyad W. Immunohistochemical expression of heat shock protein 70 in vitiligo. Ann Diagn Pathol 2013; 17: 245-9. http://dx.doi.org/10.1016/j.anndiagpath.2012.11.005
Mosenson JA, Eby JM, Hernandez C, Le Poole IC. A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol 2013; 22: 566-9. http://dx.doi.org/10.1111/exd.12183
Lerner AB. Vitiligo. J Invest Dermatol 1959; 32: 285-310. http://dx.doi.org/10.1038/jid.1959.49
Yu R, Huang Y, Zhang X, Zhou Y. Potential role of neurogenic inflammatory factors in the pathogenesis of vitiligo. J Cutan Med Surg 2012; 16: 230-44.
Bedoui S, von Horsten S, Gebhardt T. A role for neuropeptide Y (NPY) in phagocytosis: implications for innate and adaptive immunity. Peptides 2007; 28: 373-6. http://dx.doi.org/10.1016/j.peptides.2006.07.029
Khan R, Satyam A, Gupta S, Sharma VK, Sharma A. Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo. Arch Dermatol Res 2009; 301: 731-7. http://dx.doi.org/10.1007/s00403-009-0964-4
Schallreuter KU, Elwary SM, Gibbons NC, Rokos H, Wood JM. Activation/deactivation of acetylcholinesterase by H202: more evidence for oxidative stress in vitiligo. Biochem Biophys Res Commun 2004; 315: 502-8. http://dx.doi.org/10.1016/j.bbrc.2004.01.082
Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991; 97: 1081-5. http://dx.doi.org/10.1111/1523-1747.ep12492612
Dammak I, Boudaya S, Ben Abdallah F, et al. Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo. Int J Dermatol 2009; 48: 476-80. http://dx.doi.org/10.1111/j.1365-4632.2009.03998.x
Prignano F, Pescitelli L, Becatti M, Di et al. Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. J Dermatol Sci 2009; 54: 157-67. http://dx.doi.org/10.1016/j.jdermsci.2009.02.004
Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008; 159: 1051-76. http://dx.doi.org/10.1111/j.1365-2133.2008.08881.x
Jimbow K. Tuberous sclerosis and guttate leukodermas. Semin Cutan Med Surg 1997: 16: 30-5. http://dx.doi.org/10.1016/S1085-5629(97)80033-8
Herrath MG, OldstoneMB. Virus induced autoimmune disease. Curr Opin Immunol 1996; 8: 878-85. http://dx.doi.org/10.1016/S0952-7915(96)80019-7
Taieb A, Alomar A, Böhm M, et al. Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum Consensus. Br J Dermatol 2013; 168: 5-19. http://dx.doi.org/10.1111/j.1365-2133.2012.11197.x
Lotti T, Berti S, Moretti S. Vitiligotherapy. Expert Opin Pharmacother 2009; 10: 2779-85. http://dx.doi.org/10.1517/14656560903357509
Gawkrodger DJ, Ormerod AD, Shaw L, et al. Vitiligo: concise evidence based guidelines on diagnosis and management. Postgrad Med J 2010; 86: 466-71. http://dx.doi.org/10.1136/pgmj.2009.093278
Oiso N, Suzuki T, Wataya-Kaneda M, et al. Guidelines for the diagnosis and treatment of vitiligo in Japan. J Dermatol 2013; 40: 344-54. http://dx.doi.org/10.1111/1346-8138.12099
Felsten LM, Alikhan A, Petronic Rosic-V. Vitiligo: a comprehensive overview. Part II: treatment options and approach to treatment. J Am Acad Dermatol 2011; 65: 493-514. http://dx.doi.org/10.1016/j.jaad.2010.10.043
Basta-Juzbašić A. Poremećaji pigmentacije i diskromije. In: Lipozenčić i sur., edt. Dermatovenerologija, Zagreb: Medicinska naklada; 2008; 391-2.
Anbar TS, El-Sawy AE, Attia SK, et al. Effect of PUVA therapy on melanocytes and keratinocytes in non-segmental vitiligo: histopathological, immuno-histochemical and ultrastructural study. Photodermatol Photoimmunol Photomed 2012; 28: 17-25. http://dx.doi.org/10.1111/j.1600-0781.2011.00631.x